Syngene Q2 FY27: PAT -52% YoY to ₹32 Cr as margin rebounds off Q1's low
PAT -52.01% YoY · revenue -8.55% · margins compressing · beat vs street
₹832.7 Cr
-8.55% YoY
₹32.2 Cr
-52.01% YoY
3.74%
-3.5pp YoY
₹0.8
Syngene's consolidated revenue came in at ₹832.7 Cr, down 8.6% YoY from ₹910.6 Cr but up 13.1% sequentially from Q1's ₹736.0 Cr. Consolidated PAT of ₹32.2 Cr fell 52% YoY from ₹67.1 Cr, though it marks a clear sequential turnaround from Q1's ₹9 Cr net loss. The quarter carried a ₹6.7 Cr exceptional charge for employee termination benefits (Note 7) against none in the year-ago quarter; stripping it out, adjusted PAT is roughly ₹36.8 Cr, still down ~45% YoY. Standalone PAT of ₹48.7 Cr (EPS ₹1.21) diverges meaningfully from consolidated PAT of ₹32.2 Cr (EPS ₹0.80) — the ~₹16 Cr gap reflects losses/consolidation drag at the US and manufacturing subsidiaries, a materially different picture between the two bases worth flagging.
Q2 FY-2027 vs prior quarters
Operating margin (EBITDA/revenue, computed) recovered sharply to ~21.1% this quarter from ~10.5% in Q1, closing most of the gap to the year-ago 21.9% OPM — tangible evidence that cost actions taken after Q1's biologics-contract loss are working. Net margin, however, stayed compressed at 3.9% versus 7.25% a year ago on the smaller revenue base. Finance costs (₹10.0 Cr) and depreciation (₹111.7 Cr) stayed elevated, consistent with continuing capex — consolidated capital work-in-progress rose to ₹1,140.6 Cr from ₹1,040.4 Cr at FY26-end.
The stock went into the print at ₹366.2, down 3.7% over the past month of trading.
FY27 single-digit revenue decline in rupees (revised from flat); EBITDA margins mid-20s maintained; H1 weak, H2 stronger; FY28 return to profitable growth expected.
— This quarter: met
Against the ~₹700-750 Cr revenue range flagged in our pre-result preview, the ₹832.7 Cr print is a clear beat; the Street's FY27 EPS consensus of ₹9.90 implied expectations of stabilization, which this quarter's swing back to profit supports, though the YoY profit decline shows the recovery isn't complete. Management's prior guidance (Q1 FY27 call) called for a single-digit FY27 revenue decline, mid-20s EBITDA margins, and a weak H1 with a stronger H2; H1 FY27 consolidated revenue of ₹1,568.7 Cr is down 12.1% YoY from ₹1,785.1 Cr, steeper than the guided full-year decline but consistent with management's own framing that H1 would be the weak half. Margin at 21.1% this quarter remains short of the guided mid-20s band but is trending toward it, so guidance looks on track rather than missed or beaten outright. The quarter also saw continued leadership churn — Head of Corporate Affairs resigned September 21, 2026, following director Kush Parmar's July 29, 2026 exit — alongside the ongoing voluntary liquidation of subsidiary Syngene Manufacturing Solutions (initiated June 15, 2026). No management press release commentary was available to cross-check against the filing.
W1
H2 FY27 revenue must outperform H1's -12.1% YoY decline for the full year to land within management's guided single-digit decline
W2
EBITDA margin path toward management's mid-20s FY27 target from this quarter's ~21.1%
W3
Completion status of Syngene Manufacturing Solutions' voluntary liquidation, ongoing as of September 30, 2026
Current quarter carries a ₹6.7 Cr exceptional charge (employee termination benefits, Note 7) vs no exceptional item in Q2 FY26; prior quarter (Q1 FY27) had a larger ₹13.5 Cr exceptional charge. PDF is clean/digital, all tables legible, arithmetic ties out on both bases.
New CEO's first print: stabilization signal or sustained headwind?
Q1 saw a 56% EBITDA collapse from the loss of a major biologics contract. With Siddharth Mittal three months into his tenure, the Street watches for evidence that cost correction is taking hold and that FY28 recovery is on track.
Syngene enters Q2 FY27 in the midst of a operational overhaul. The loss of a major commercial biologics contract and manufacturing discontinuations have fundamentally reset the earnings base: Q1 consolidated revenue fell 16% year-on-year to ₹736 Cr, with operating EBITDA down 56% to ₹91 Cr and the company swinging to a net loss of ₹9 Cr from a ₹87 Cr profit. Management guided for a single-digit revenue decline in full-year FY27 and EBITDA margins to recover to the mid-20s as cost correction takes hold. The real test now: does Q2 show stabilization, or does the revenue headwind persist?
~₹700–750 Cr
Align with guided single-digit FY27 decline; Q1 -16% YoY suggests stabilization vs further deterioration
mid-20s%
Down from historical 25–30%; recovers as cost base realigns and plant utilization improves through the year
Revenue tracking guidance, margin beat vs Q1's 12.4%, early proof of cost discipline
Evidence that the new MD's operational focus is translating to real savings and that FY28 recovery is credible
Revenue miss vs guidance, margin flat or compressed, further contract/capability exits
Would extend the distress cycle and delay FY28 recovery; pressure on FY28 guidance and Street confidence
On track for FY27 guidance?
Q1 represented the trough: Q2 and H2 should show stabilization if the single-digit revenue-decline guide is to hold. The company has already taken the hit from the biologics contract loss; FY27 is now a cost-correction year with EBITDA margins expected to bottom, stabilize around mid-20s, and inflect upward from FY28 as asset utilization picks up and the new CEO's operational discipline takes deeper root. Watch whether Q2 revenue trends closer to flat QoQ (stability) or shows further seasonal softness, and whether cost actions (headcount, capex deferral, facility rationalization) are materializing in EBITDA. The Street is not pricing in a margin recovery; a Q2 beat on operating leverage would matter.
Since last quarter: the management rebuild
1 · New MD & CEO (July 1)
Siddharth Mittal, former Biocon MD & CEO, took charge. Street sees him as a strong operator with GLP-1 and biopharma commercialization experience. His mandate: sharpen commercial edge, strengthen delivery excellence, bring discipline to execution. Q2 will be his first full print under new stewardship.
2 · Departures (July–September)
Peter Bains (outgoing MD), Surender Sharma (General Counsel), Kush Parmar (Independent Director), and Pramuch Goel (Head Corporate Affairs) all departed. Institutional continuity risk; watch for further exits. Bulk / block deals in the ₹481–486 range (late August–September) show trading but no major insider buying—neutral signal.
3 · FII selling pressure
FII stake fell 2.08pp QoQ to 11.82%. Dividend (12.5% for FY26) was remitted in September, a positive for retail, but FII exodus reflects rerating down amid execution risk. Watch whether Q2 steadiness and FY28 guidance reset bring confidence back.
4 · Tax refund (July)
Received ₹8.62 Cr Income Tax refund for AY 2014-15 (NFAC order). One-off benefit; not recurring. Improves near-term cash but doesn't offset operational headwind.
What to watch on result day (October 27)
1 · Revenue: stabilization or continued slide?
If Q2 revenue is ~₹720–750 Cr (i.e., Q1-like or modestly better), the single-digit FY27 decline is credible. If it dips below ₹700 Cr, guidance risk rises. Watch for quarterly trends, geography mix (India vs US), and CRDMO utilization commentary.
2 · EBITDA margin: cost actions visible?
Q1 margin was 12.4%. Expect Q2 in the 15–20% range if cost cuts are kicking in. Any margin below 12% or compression vs Q1 suggests headwinds persist. Mid-20s is the FY27 guide; Q2 won't get there, but the trajectory matters.
3 · FY28 guidance: recovery credible?
New CEO will likely address FY28 expectations. Street is pricing in a rebound; any downward revision would spook already-weak FII confidence. Watch tone on CRDMO pipeline, capacity utilization, and commercial wins.
Syngene's Q2 print comes at an inflection: the worst of the biologics contract loss is behind, the new CEO is three months in, and Street expectations are calibrated for stabilization and FY28 recovery. Revenue around ₹720–750 Cr with EBITDA margin stabilizing (or showing early improvement) would reassure that the cost correction is on track and that the single-digit FY27 decline is defensible. Any miss on stabilization—further revenue slide or margin compression—risks reigniting the selloff and pushing out recovery timelines. The stock trades at 30% discount to consensus target (₹501.88 vs ₹376.45), but FII exits show patience is thin.
Read the result for three signals: (1) Does the new MD's cost discipline show up in Q2 margins? (2) Is the CRDMO revenue base stabilizing or eroding further? (3) Does management's FY28 guidance instill confidence, or hint at further downside? A beat on margin with steady revenue would justify the 30% upside; a miss would test Street support below current levels.